BRISBANE, Calif.--(BUSINESS WIRE)--
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA)
today announced the filing by GSK of a regulatory submission with the US
Food and Drug Administration for the once-daily, closed triple
combination therapy fluticasone furoate/umeclidinium/vilanterol
(FF/UMEC/VI 100/62.5/25 mcg) for patients with chronic obstructive
pulmonary disease (COPD). This follows the announcement earlier this
year of plans to bring forward the timing of the US filing from the
first half of 2018.
The closed triple combination therapy comprises three medicines:
fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a
long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting
beta2-adrenergic agonist (LABA), delivered once-daily in
GSK's Ellipta® dry powder inhaler.
The US regulatory submission of the closed triple therapy comprises a
New Drug Application for the maintenance treatment of patients with
COPD, including chronic bronchitis and emphysema. It is based on data
from the closed triple combination therapy development programme, as
well as data from studies with FF, UMEC and VI either alone or in
combination.
Dave Allen, Head of Respiratory R&D, said, "COPD is a progressive
disease and its impact on patients can worsen over time. As reflected in
the recently updated GOLD COPD Strategy*, for those patients with
advanced disease, multiple therapies such as ICS/LAMA/LABA combinations
are often required and are typically delivered via two or more inhalers
with potentially differing dose regimens. This first regulatory
submission of our closed triple therapy brings us a step closer to
providing a once-daily treatment in a single Ellipta inhaler as an
alternative option for those patients who require multiple therapies."
Mike Aguiar, CEO of Innoviva, Inc., added "We are delighted that the US
submission has been achieved some 18 months earlier than planned. If
approved, FF/UMEC/VI as a once daily triple combination in a single
inhaler could be a meaningful addition to the treatment options
available for advanced COPD patients."
A regulatory filing in the EU is planned in the coming weeks and is
expected to be followed by submissions in other countries beginning in
2017. The closed triple combination of FF/UMEC/VI is not approved for
use anywhere in the world.
*The Global Strategy for the Diagnosis, Management and Prevention of
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)
2017. Available from: http://goldcopd.org.
Accessed: November 2016
About COPD
COPD is a disease of the lungs that includes chronic bronchitis,
emphysema or both. COPD is characterised by obstruction to airflow that
interferes with normal breathing. COPD is thought to affect 329 million
people worldwide.
Long-term exposure to lung irritants that damage the lungs and the
airways are usually the cause of COPD. Cigarette smoke, breathing in
second hand smoke, air pollution, chemical fumes or dust from the
environment or workplace can all contribute to COPD. Most people who
have COPD are at least 40 years old when symptoms begin.
Innoviva - Innoviva is focused on bringing compelling new
medicines to patients in areas of unmet need by leveraging its
significant expertise in the development, commercialization and
financial management of bio-pharmaceuticals. Innoviva's portfolio is
anchored by the respiratory assets partnered with Glaxo Group Limited
(GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®,
which were jointly developed by Innoviva and GSK. Under the agreement
with GSK, Innoviva is eligible to receive associated royalty revenues
from RELVAR®/BREO® ELLIPTA®,
ANORO® ELLIPTA® and, if approved and
commercialized, VI monotherapy, as well. In addition, Innoviva retains a
15 percent economic interest in future payments made by GSK for
earlier-stage programs partnered with Theravance Biopharma, Inc.,
including the closed triple combination therapy for COPD. For more
information, please visit Innoviva's website at www.inva.com.
GSK - one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live longer.
For further information please visit www.gsk.com.
RELVAR®, BREO®, ANORO® and ELLIPTA®
are trademarks of the GlaxoSmithKline group of companies.
GSK cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement, are
subject to risks and uncertainties that may cause actual results to
differ materially from those projected. Such factors include, but are
not limited to, those described under Item 3.D 'Risk factors' in the
company's Annual Report on Form 20-F for 2015.
Innoviva forward-looking statements
This press release contains certain "forward-looking" statements as that
term is defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, statements relating to goals, plans,
objectives and future events, including the development, regulatory and
commercial plans for closed triple combination therapy and the potential
benefits and mechanisms of action of closed triple combination therapy.
Innoviva intends such forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in
Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve substantial risks, uncertainties and assumptions.
These statements are based on the current estimates and assumptions of
the management of Innoviva as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances, assumptions
and other factors that may cause the actual results of Innoviva to be
materially different from those reflected in the forward-looking
statements. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are
described under the headings "Risk Factors" and "Management's Discussion
and Analysis of Financial Condition and Results of Operations" contained
in Innoviva's Annual Report on Form 10-K for the year ended December 31,
2015 and Quarterly Report on Form 10-Q for the quarter ended September
30, 2016, which are on file with the Securities and Exchange Commission
(SEC) and available on the SEC's website at www.sec.gov.
In addition to the risks described above and in Innoviva's other filings
with the SEC, other unknown or unpredictable factors also could affect
Innoviva's results. No forward-looking statements can be guaranteed and
actual results may differ materially from such statements. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. The information in this press release is
provided only as of the date hereof, and Innoviva assumes no obligation
to update its forward-looking statements on account of new information,
future events or otherwise, except as required by law. (INVA-G).
|
Registered in England & Wales:
No. 3888792
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
View source version on businesswire.com: http://www.businesswire.com/news/home/20161120005021/en/
GSK enquiries:
UK Media enquiries:
Simon Steel, +44 (0)
20 8047 5502, (London)
David Daley, +44 (0) 20 8047 5502, (London)
Sarah
Macleod, +44 (0) 20 8047 5502, (London)
or
US Media enquiries:
Sarah
Alspach, +1-202-715-1048, (Washington, DC)
Sarah Spencer,
+1-215-751-3335, (Philadelphia)
Karen Hagens, +1-919-483-2863,
(North Carolina)
or
Analyst/Investor enquiries:
Tom
Curry, +1-215-751-5419, (Philadelphia)
Gary Davies, +44 (0) 20 8047
5503, (London)
James Dodwell, +44 (0) 20 8047 2406, (London)
Jeff
McLaughlin, +1-215-751-7002, (Philadelphia)
or
Innoviva,
Inc. enquiries:
Investor Relations:
Eric d'Esparbes,
+1-650-238-9605
investor.relations@inva.com
(Brisbane,
Calif.)
Source: Innoviva
News Provided by Acquire Media